Business
Intellia Therapeutics Presents New Interim Data from First-in-Human Study of NTLA-2002 for the Treatment of Hereditary Angioedema (HAE) at the American College of Allergy, Asthma & Immunology 2022 Annual Scientific Meeting
Robust reductions in plasma kallikrein levels and HAE attack rates observed at all doses testedAll patients treated in the 25 mg and 75 mg cohorts have an
About this update from Intellia Therapeutics, Inc.
[{"type":"text","content":"Robust reductions in plasma kallikrein levels and HAE attack rates observed at all doses testedAll patients treated in the 25 mg and 75 mg cohorts have an ongoing attack-free interval through latest follow-up First three patients treated have an ongoing attack-free interval of 5.5 – 10.6 months after a single dose of NTLA-2002 NTLA-2002 was generally well-tolerated at all dose levels Intellia to host investor event to discuss updated data from Phase 1/2 study of NTLA-2002, its second systemically administered in vivo CRISPR candidate, on Monday, November 14, at 8:00 a.m. ET CAMBRIDGE, Mass., Nov. 12, 2022 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage genome editing company focused on developing potentially curative therapeutics leveraging CRISPR-based technologies, today announced updated data from an ongoing Phase 1/2 clinical study of NTLA-2002 for the treatment of hereditary angioedema (HAE). The interim analyses were shared today in a Distinguished Industry Abstract oral presentation at the American College of Allergy, Asthma & Immunology (ACAAI) 2022 Annual Scientific Meeting, being held November 10 – 14 in Louisville, Kentucky. The data presented are from 10 adult patients with HAE in the Phase 1, dose-escalation portion of the study, with a data cut-off date of September 28, 2022. Single doses of 25 mg (n=3), 50 mg (n=4) and 75 mg (n=3) of NTLA-2002 were administered via intravenous infusion, and changes from baseline values of plasma kallikrein protein were measured for each patient. Plasma Kallikrein Reduction Administration of NTLA-2002 led to deep, dose-dependent reductions in plasma kallikrein as described below, based on complete cohort biomarker data availability. For the 25 mg and 75 mg cohorts, these deep reductions in plasma kallikrein were sustained through the observation period, which ranged from week 16 to week 32. CohortMean plasma kallikrein reduction at latest follow-up 25 mg (n=3)64% (week 32)50 mg (n=4)81% (day 22)75 mg (n=3)92% (week 16) HAE Attack Rate Reduction HAE attack rates are measured in the dose-escalation portion of the study, with the first analysis occurring at the end of the pre-specified 16-week primary observation period. To date, all patients in the 25 mg and 75 mg dose cohorts have reached the end of this initial observation period in ongoing f...